13 Amendments of Michèle RIVASI related to 2017/2254(INI)
Amendment 1 #
Draft opinion
Recital –A (new)
Recital –A (new)
-A. whereas the main cause of AMR is the excessive use of antibiotics and up to half of antibiotics used in humans are unnecessary and inappropriate, changing the way antibiotics are used is the single most important action needed to slow down the development of AMR;
Amendment 2 #
Draft opinion
Recital –A a (new)
Recital –A a (new)
-Aa. whereas the consumption of antibiotics decreases as knowledge on the correct use of antibiotics increases;
Amendment 3 #
Draft opinion
Recital –A b (new)
Recital –A b (new)
-Ab. whereas the spread of antimicrobials has contributed to the declining effectiveness of existing antimicrobials and more research is needed to develop alternative treatments;
Amendment 4 #
Draft opinion
Recital –A c (new)
Recital –A c (new)
-Ac. whereas development and spread of antimicrobials in the environment is also a growing concern, requiring further research;
Amendment 5 #
Draft opinion
Recital A
Recital A
A. whereas antimicrobial resistance (AMR)-related challenges will tremendously increase in the years ahead and inaction is projected to cause yearly millions of deaths globally, effective action is primarily reliant on better knowledge, prevention and reduced usage of antimicrobials, as well as on continued, cross-sectorial investments in research & innovation (R&I), so that better tooland alternative treatments, products and approaches can be developed following a One Health approach;
Amendment 12 #
Draft opinion
Recital A a (new)
Recital A a (new)
Aa. whereas phagetherapy is considered an effective complementary treatment to antibiotics that is showing positive results, is gaining growing scientific interest including by the pharmaceutical companies, but is however lacking sufficient research support at EU level;
Amendment 22 #
Draft opinion
Recital C
Recital C
C. whereas different funding instruments under H2020 willmight deliver research results on AMR, in particular: the Innovative Medicines Initiative (IMI), with a focus on all aspects of antibiotic development including research into AMR mechanisms, drug discovery, drug development, and economics and stewardship; the European and Developing Countries Clinical Trials Partnership (EDCTP), with a focus on the development of new and improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria; the Joint Programming Initiative on AMR (JPIAMR), with a focus on consolidation of otherwise fragmented national research activities; the European Research Council (ERC), with its ‘investigator-driven’ or ‘bottom-up’ research projects; the InnovFin Infectious Diseases Financial Facility (IDFF), for close-to-market projects; and the SME Instrument and Fast Track to Innovation (FTI) which support SMEs in developing novel solutions and tools to prevent, diagnose and treat infectious diseases and improve infection control;
Amendment 27 #
Draft opinion
Paragraph –1 (new)
Paragraph –1 (new)
-1. Emphasises the need to decrease the usage of antibiotics in order to slowdown the further development of AMR;
Amendment 29 #
Draft opinion
Paragraph 1
Paragraph 1
1. Emphasises the need to increase funding for R&I in epidemiology and immunology for AMR pathogens and healthcare-associated infections (HAI) as well as to increase the funding of alternative treatments for humans and animals;
Amendment 35 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Calls to invest the EU funds in the context of Horizon 2020 and the next EU Framework Programme into research and development of alternative, albeit complementary, treatments such as phagotherapy;
Amendment 40 #
Draft opinion
Paragraph 1 b (new)
Paragraph 1 b (new)
1b. Stresses the urgent need for in- depth research on the impact of presence antimicrobial substances on food crops and animal feed on the development of AMR, and on microbial community in soil;
Amendment 48 #
Draft opinion
Paragraph 2
Paragraph 2
2. Calls for the development of various push and pull incentives to create new medicines and medical devicefind and implement new treatments; believes that incentives are meaningful when they are sustainable over the long term, stimulate investment across the entire product development and life cycle, target key public health priorities, and support appropriate medicinal use;
Amendment 64 #
Draft opinion
Paragraph 3
Paragraph 3
3. Expresses the urgent need to foster partnerships throughout the EU in order to enhance the exchange of best practices in reducing the use of antibiotics and improve knowledge on AMR;